IPO - Vivos Therapeutics, Inc.

Form Type: 424B1

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004472

Filing Summary: This prospectus relates to the offer for sale of up to an aggregate of 854,332 shares of Common Stock of Vivos Therapeutics, Inc., structured as part of a securities purchase agreement with selling stockholders. It includes 709,220 shares underlying December 2024 Warrants, 95,467 shares from placement agent warrants issued as part of the December 2024 Offering, and 49,645 shares from another placement agent warrant in connection with a September 2024 agreement. The document indicates that no proceeds will be received from the resale of shares by the selling stockholders. However, proceeds from potential warrant exercises may be used for general corporate purposes. The Common Stock is listed on Nasdaq under the symbol 'VVOS.' As of January 30, 2025, the last reported sale price was $3.93. The prospectus highlights risk factors associated with investing in Common Stock and states that the company is an emerging growth entity subject to reduced reporting requirements. Investors are cautioned about speculative risks involved.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004057

Filing Summary: Vivos Therapeutics, Inc. filed an amended registration statement with the SEC on January 29, 2025, under Form S-1/A. This amendment is specifically intended to remove reliance on certain information incorporated by reference from previous filings. The registration relates to the sale of up to 854,332 shares of Common Stock by named selling stockholders. The offering includes 709,220 shares underlying warrants from a private placement conducted on December 22, 2024, and additional shares associated with placement agent warrants from that offering. The company does not anticipate any proceeds from the resale but may receive funds upon the exercise of these warrants, which will be allocated for general corporate or working capital needs. This filing marks a step in Vivos Therapeutics' progression towards its initial public offering, ensuring compliance and transparency for potential investors.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-22

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003115

Filing Summary: Vivos Therapeutics, Inc. filed an S-1 registration statement for the proposed sale of up to 854,332 shares of common stock by selling stockholders, including warrants issued in private placements. The filing outlines the company's focus on developing innovative treatments for obstructive sleep apnea (OSA) and related conditions through proprietary oral appliances, diagnostic tools, and multi-disciplinary treatment strategies. Key highlights include their unique FDA-cleared devices aimed at treating OSA, particularly the CARE oral appliance, which represents a significant advancement in treatment options not requiring surgical intervention. The company emphasizes its extensive ongoing collaboration with healthcare providers and is poised for market expansion through various strategies, including a recently revamped Treatment Navigator program to better assist patients in accessing care. The filing indicates no direct proceeds from the sale of shares but notes that there may be future funding from the exercise of warrants. Vivos is classified as an emerging growth company, implying reduced public reporting requirements, which may appeal to potential investors. The registration is expected to become effective soon after approval from the SEC.

Document Link: View Document